Tempus
Healthcare technology company using AI and genomics for precision medicine and cancer treatment.
About Tempus
Tempus is a healthcare technology company that leverages artificial intelligence and genomic sequencing to advance precision medicine, particularly in oncology. Founded in 2015 by Eric Lefkofsky, the company builds a platform that analyzes clinical and molecular data to help physicians make more informed treatment decisions. Tempus operates one of the largest genomic databases in the world and provides diagnostic testing, data analytics, and AI-powered insights to healthcare providers. The company went public in 2024 and continues to expand its precision medicine capabilities.
Investors & Backers
Tempus has received investment from 4 venture capital firms.
Frequently Asked Questions
What does Tempus do?
Healthcare technology company using AI and genomics for precision medicine and cancer treatment.
Who invested in Tempus?
Tempus has received investment from Frist Cressey Ventures, Hyde Park Angels, TechNexus Venture Collaborative, Two Sigma Ventures. These venture capital firms and investors provide both capital and strategic support.
How much funding has Tempus raised?
Tempus has raised $1.4B in total funding, with their most recent round being a IPO. The company operates in the Digital Health sector.
When was Tempus founded?
Tempus was founded in 2015 and is headquartered in Chicago, IL.
What sector is Tempus in?
Tempus operates in the Digital Health sector. Healthcare technology company using AI and genomics for precision medicine and cancer treatment.
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Company Details
- Sector
- Digital Health
- Headquarters
- Chicago, IL
- Founded
- 2015
- Status
- Active
- Last Funding Stage
- IPO
- Total Funding
- $1.4B
- Valuation
- $8.1B
